Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of asthma, and presently has reversibility over pre-bronchodilator forced expiratory volume in 1 second (FEV1) of ≥ 20% at screening~* Percent of predicted FEV1 ≥ 40% and ≤ 80% at screening~* Inhaled corticosteroid (ICS) ≥ 200 and ≤ 1000/μg/day fluticasone powder or equivalent~* Ongoing asthma symptoms with asthma control questionnaire (ACQ) composite score at screening and baseline ≥ 1.5 points~Exclusion Criteria:~* History of chronic obstructive pulmonary disease (COPD) or other chronic pulmonary condition other than asthma~* History of allergic bronchopulmonary aspergillosis~* Respiratory infection within 4 weeks of screening or 1 week of baseline visit~* Subject has known history of Crohn's disease~* Subject has any other significant concurrent medical condition of laboratory abnormalities, as defined in the study protocol~* Subject has previously used any anti-interleukin-17 (IL17) biologic therapy~* Subject is pregnant or breastfeeding, or planning to become pregnant while enrolled in the study~* Female subject is unwilling to use highly effective methods of birth control unless 2 years post-menopausal or surgically sterile~* Subject has severe depression measured by Personal Health Questionnaire Depression Scale (PHQ-8) or suicidal ideation/behavior as measured by and Columbia Suicide Severity Rating Scale (e-CSSRS)~* Subject has a history or evidence of psychiatric disorder or substance abuse considered by the Investigator to pose a risk to subject safety

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo administered by subcutaneous injection on day 1, week 1, week 2 and every 2 weeks thereafter for 24 weeks.
- Brodalumab 210 mg (Type: EXPERIMENTAL): Participants received 210 mg brodalumab administered by subcutaneous injection on day 1, week 1, week 2, and every 2 weeks thereafter for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).